Topics

Cerevance Achieves Key Endpoints in Phase 1 Clinical Trial of Novel Parkinson’s Disease Drug CVN424

10:17 EDT 30 Apr 2019 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
Results Demonstrate Safety of CVN424 and Enable Initiation of Phase 2 Study in Patients Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, has successfully completed its Phase 1...

Other Sources for this Article

Cerevance Contact:
Robert Middlebrook, +1.408.220.5722

Media Contact:
Cait Williamson, Ph.D., cait@lifescipublicrelations.com, +1.646.751.4366

NEXT ARTICLE

More From BioPortfolio on "Cerevance Achieves Key Endpoints in Phase 1 Clinical Trial of Novel Parkinson’s Disease Drug CVN424"

Quick Search

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...